Alkermes’ Antipsychotic Combo Faces US FDA Questions On Metabolic Effects, Opioid-Related Safety
ALKS 3831, which combines olanzapine with the mu opioid receptor antagonist samidorphan, was associated with less weight gain compared to olanzapine alone but showed no benefit on metabolic parameters; in advisory committee briefing documents, agency raises theoretical safety concerns about drug’s opioid antagonistic effects in real-world settings.
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The latest submission and expedited review program news and highlights from our US FDA Performance Tracker.
The latest drug development news and highlights from our US FDA Performance Tracker.